Available to mentor
I am a medical oncologist specializing in breast oncology at the University of Michigan Rogel Cancer Center. As a translational scientist, I am driven by the challenges I encounter when treating patients in the clinic. My research interest is in breast cancer stem cell therapeutics, in particular identifying new strategies to target cancer stem cells in order to improve current therapies. Additionally, in my own laboratory and with collaborators, I have studied methods to isolate and analyze circulating tumor cells with a focus on stemness. My clinical research and laboratory skills are particularly well-suited to the current project proposal. My laboratory has expertise in the assays described in the proposal, and I also have experience developing and running clinical trials. Our recent preclinical work provides a strong foundation to support the Aims of this proposal.
Burness Lab - Research Google Scholar Profile University of Michigan Health Michigan Medicine
-
Fellowship Hematology/OncologyUniversity of Chicago Medical Center, Internal Medicine, 2011
-
ResidencyThe Johns Hopkins Hospital, Internal Medicine, 2008
Breast Cancer Stem Cells
Tumor Biology
Identifying therapeutic targets and improving therapeutic regimens
-
Shah NM, Scott DM, Kandagatla P, Moravek MB, Cobain EF, Burness ML, Jeruss JS. Ann Surg Oncol, 2019 May; 26 (5): 1214 - 1224.Journal ArticleYoung Women with Breast Cancer: Fertility Preservation Options and Management of Pregnancy-Associated Breast Cancer.
DOI:10.1245/s10434-019-07156-7 PMID: 30680478 -
Burness ML, Grushko TA, Olopade OI. Cancer J, 2010 16 (1): 23 - 32.Journal ArticleEpidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?
DOI:10.1097/PPO.0b013e3181d24fc1 PMID: 20164687 -
Wu L, Taichman LS, Burness M, Mattison D, Barton D, Pearlman M. Contraception, 2019 Oct; 100 (4): 338 - 338.Proceeding / Abstract / Poster"Here's Your Options; Abstinence, Condom, Diaphragm, That's it." A Mixed Methods Study of Patient and Health Care Provider Perspectives Regarding Contraception for Young People with Breast Cancer
DOI:10.1016/j.contraception.2019.07.109 -
2024 Mar 13;Presentation"BETting on Breast Cancer Stem Cells"
-
Sharma D, Hager CG, Shang L, Tran L, Zhu Y, Ma A, Magnuson B, Lesko MW, Wicha MS, Burness ML. Breast Cancer Res, 2023 Nov 15; 25 (1): 144Journal ArticleThe BET degrader ZBC260 suppresses stemness and tumorigenesis and promotes differentiation in triple-negative breast cancer by disrupting inflammatory signaling.
DOI:10.1186/s13058-023-01715-3 PMID: 37968653 -
Sharma D, Hager CG, Shang L, Tran L, Zhu Y, Ma A, Magnuson B, Lesko MW, Wicha MS, Burness ML. Breast Cancer Res, 2023 Nov 15; 25 (1): 144Journal ArticleThe BET degrader ZBC260 suppresses stemness and tumorigenesis and promotes differentiation in triple-negative breast cancer by disrupting inflammatory signaling.
DOI:10.1186/s13058-023-01715-3 PMID: 37968653 -
Calfa CJ, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Burness ML, Gogineni K, Rohatgi N, Al Baghdadi T, Conlin A, Gaba A, Hamid O, Krishnamurthy J, Gavini NJ, Gold PJ, Rodon J, Rueter J, Thota R, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. JCO Precis Oncol, 2024 Feb; 8: e2300513Journal ArticleSunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
DOI:10.1200/PO.23.00513 PMID: 38354330 -
Calfa CJ, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Burness ML, Gogineni K, Rohatgi N, Al Baghdadi T, Conlin A, Gaba A, Hamid O, Krishnamurthy J, Gavini NJ, Gold PJ, Rodon J, Rueter J, Thota R, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. JCO Precis Oncol, 2024 Feb; 8: e2300513Journal ArticleSunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
DOI:10.1200/PO.23.00513 PMID: 38354330
